TABLE 1.
Plasma APV pharmacokinetic parameters and treatment comparisonsa
| Treatment or comparison | AUC0-24 (μg · h/ml) | AUC0-∞ (μg · h/ml) | Cmax (μg/ml) | C12 (μg/ml) | tmax (h)d |
|---|---|---|---|---|---|
| Treatmentsb | |||||
| FPV | 20.67 (17.31-24.69) | 22.05 (18.50-26.30) | 4.73 (4.11-5.45) | 0.32 (0.25-0.40) | 1.50 (0.75-5.00) |
| FPV + MAALOX TC | 16.98 (14.32-20.14) | 18.71 (15.72-22.26) | 3.09 (2.69-3.54) | 0.36 (0.28-0.48) | 1.50 (0.75-5.00) |
| FPV + ranitidine | 14.45 (11.46-18.22) | 16.03 (12.55-20.48) | 2.31 (1.86-2.87) | 0.32 (0.24-0.42) | 1.75 (0.75-5.00) |
| Comparisonsc | |||||
| FPV + MAALOX TC vs FPV | 0.82 (0.74-0.91) | 0.85 (0.77-0.94) | 0.65 (0.57-0.76) | 1.14 (0.93-1.39) | 1.18 (0.84-1.39) |
| FPV + ranitidine vs FPV | 0.70 (0.63-0.78) | 0.74 (0.66-0.82) | 0.49 (0.42-0.57) | 0.99 (0.81-1.21) | 1.37 (1.03-1.71) |
All data are based on results for a group of 26 subjects, except for the AUC0-∞ data, which are based on a group of 24 because λz (apparent terminal phase rate constant) was not estimated from plasma APV concentration-time profiles for two subjects. All dosages were as follows: FPV, 1,400 mg; MAALOX TC, 30 ml; ranitidine, 300 mg.
For all treatment data except tmax values, geometric means are given with 95% CIs in parentheses.
For all comparison data except tmax values, geometric least-squares mean ratios are given with 90% CIs in parentheses.
The tmax treatment and comparison data are expressed as medians with ranges in parentheses and least-squares mean ratios with 90% CIs in parentheses, respectively.